# NCT05364073 (NCT05364073)

> Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

No report yet. It can be ordered.

- Drugs tested: furmonertinib
- Indication: advanced or metastatic NSCLC with EGFR/HER2 mutations

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05364073
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: ArriVent BioPharma, Inc.
- Conditions: Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; HER2 Exon 20 Mutations; EGFR Exon 20 Mutations; EGFR Uncommon Mutations, Including G719X and S768I
- Interventions: Furmonertinib; Furmonertinib; Furmonertinib; Furmonertinib; Furmonertinib
- Enrollment: 160
- Primary outcome: Stage 1: Number of incidence and severity of adverse events (AEs) as a measure of safety and tolerability of Furmonertinib
- Primary outcome: Stage 2: Overall Response Rate (ORR)

## Indexed commentary on NCT05364073 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct05364073